Form 4: Vor Biopharma Inc. Executive Eyal C. Attar Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports the disposal of 1,146 shares of common stock to cover tax obligations related to restricted stock units.
Summary
- On May 1, 2024, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., disposed of 1,146 shares of common stock.
- The shares were withheld to satisfy tax obligations related to the settlement of restricted stock units.
- The transaction price was $1.77 per share.
- Following the transaction, Attar directly owns 111,707 shares of Vor Biopharma Inc.
Sentiment
Score: 5
Explanation: This is a routine filing related to tax obligations, so it doesn't significantly impact sentiment. It's a neutral event.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This transaction is related to tax obligations from stock-based compensation, which is a common practice.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a small number of shares being disposed of to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of transaction: disposal of 1,146 shares of common stock. |
| 05/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.